After Ranbaxy and Caraco, U.S. FDA Cracks Down On Lupin, Finds Lapses At Its Mandideep Site

MUMBAI - Continuing with its crackdown on manufacturing sites of large Indian generic companies, U.S. FDA issued a Form 483 for 15 deficiencies at Lupin's manufacturing site at Mandideep situated in central India